Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating
such patients. The primary endpoint is to compare the recurrence-free survival after 1-year
or 2-year treatment with icotinib.